Allogeneic human chondrocyte is an emerging therapy that can be used for cartilage repair and other indications.
Allogeneic Human Chondrocyte Market: Introduction
Allogeneic human chondrocyte is an emerging therapy that can be used for cartilage repair and other indications. Only few players are involved in the development of this treatment procedure. Allogeneic human articular chondrocytes (hAC) could be a good alternative; however, the possibility of immunological incompatibility between recipient and hAC donor should be considered.
Read Report Overview - https://www.transparencymarketresearch.com/allogeneic-human-chondrocyte-market.html
Key Drivers and Restraints of Global Allogeneic Human Chondrocyte Market
Geriatric population and high prevalence of obesity are likely to continue to contribute to the growing prevalence of osteoarthritis (OA), placing a major burden on individuals, health systems, and social care systems across the world. Rise in incidence of OA is expected to boost the demand for improved drugs and new therapies. According to the Arthritis Foundation, 130 million individuals around the globe would be affected by osteoarthritis by the year 2050. Obesity is considered a risk factor for osteoarthritis, especially knee osteoarthritis. According to the World Health Organization, prevalence of obesity has nearly tripled since 1975, globally. In 2016, more than 650 million adults and 41 million children, under 5 years of age, were obese.
Emerging technologies that transforms the allogeneic human chondrocyte market are cartilage restoration technologies, gene therapy, stem cells, and tissue engineering. Cartilage restoration technology is broadly divided into two types: two-stage and one-stage techniques and few of these techniques are still under clinical trial in the U.S. However, these techniques are well-adopted among physicians in Europe.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=80490
High cost of treatment procedure is projected to hamper the market. Stem cell therapy may cost US$ 5,000–10,000 per treatment. In some clinics, the prices vary between US$ 7,000-8,000. Presently, outside the U.S., cultured stem cell procedures are being offered. Cultured stem cell procedures are employed to treat orthopedic and degenerative conditions.
Musculoskeletal System Disorders Segment Expanded Significantly
Based on application, the global allogeneic human chondrocyte market can be divided into osteoarthritis, musculoskeletal system disorders, and others
The osteoarthritis segment dominated the global market in 2019. It is projected to sustain its position during the forecast period. Rise in geriatric population with osteoarthritis issues across the world has augmented the number of surgeries performed in the last few years.
Request for Analysis of COVID-19 Impact on Allogeneic Human Chondrocyte Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=80490
However, the musculoskeletal system disorders segment is estimated to expand at a notable CAGR during the forecast period. According to the State of Musculoskeletal Health, 2019 report, prevalence of musculoskeletal conditions in the U.K. was 15,899,000, in 2017
Hospitals Segment to Dominate Global Allogeneic Human Chondrocyte Market
Based on end-user, the global allogeneic human chondrocyte market can be segregated into hospitals, specialty clinics, and ambulatory surgical centers
In terms of revenue, the hospitals segment accounted for a prominent share of the market in 2019 owing to a large number of orthopedic procedures performed in hospitals owing to the presence of integrated healthcare facilities and availability of technologically advanced infrastructure at hospitals. The number of orthopedic surgery procedures performed worldwide was approximately 22.3 million in 2017.
Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=80490
North America to Dominate Global Allogeneic Human Chondrocyte Market
In terms of region, the global allogeneic human chondrocyte market can be divided into: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
North America accounted for a significant share of the global allogeneic human chondrocyte market in 2019 followed by Europe. Increase in prevalence of osteoarthritis in patients, rise in healthcare expenditure, and increase in investments are attributed to the major share held by North America in the global allogeneic human chondrocyte market. Innovative therapy and upcoming product launches in North America are expected to further propel the market in the region by the end of 2030. As per CDC, osteoarthritis affects over 32.5 million adults in the U.S. every year.
The market in developing countries in Asia Pacific is projected to expand at a notable CAGR during the forecast period. Increase in patient population, key players focus on providing osteoarthritis treatments, and increase in public & private healthcare spending are fueling the allogeneic human chondrocyte market in Asia Pacific. Awareness and adoption of novel drugs play a major role in propelling the allogeneic human chondrocyte market.
Pre Book Allogeneic Human Chondrocyte Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=80490<ype=S
Key Manufacturers Operating in Market
The global allogeneic human chondrocyte market was highly fragmented in 2019. Key manufacturers operating in the global market are:
- Kolon TissueGene, Inc
- ISTO Technologies Inc.
- Zimmer Biomet
- Genzyme
- CellGenix
- EMD Serono
Browse more Reports by Transparency Market Research:
Medical Talent Management IT Market: https://www.transparencymarketresearch.com/medical-talent-management-it-market.html
Air-assisted Patient Transfer Systems Market: https://www.transparencymarketresearch.com/air-assisted-patient-transfer-systems-market.html
Healthcare Payer Services Market: https://www.transparencymarketresearch.com/healthcare-payer-services-market.html
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/